SK Biopharmaceuticals (326030) Q2 2025 earnings summary

Executive summary

• Q2 2025 revenue reached KRW 176.3B, up 22.1% sequentially and 31.6% year-over-year, driven by record XCOPRIⓇ sales.

• Focus on CNS and oncology drug development, with global commercialization of key products XCOPRI (cenobamate) and SUNOSI (solriamfetol).

• Strong global licensing and partnership network, including major deals in the US, Europe, Japan, China, and other regions.

• Robust R&D pipeline with multiple late-stage and early-stage assets, and significant investment in AI-driven drug discovery.

• Operating profit surged to KRW 61.9B, a 141.1% increase from the previous quarter and 137.6% year-over-year.

Financial highlights

• H1 2025 consolidated revenue: KRW 320.7B, down from KRW 547.6B in FY2024.

• XCOPRIⓇ US sales reached KRW 154.1B ($109.5M), up 15.6% sequentially and 46.5% year-over-year.

• Gross profit rose to KRW 166.4B, up 24.3% sequentially and 32.8% year-over-year.

• Net profit for Q2 was KRW 29.5B, up 50.5% from the previous quarter and 20.2% year-over-year.

• Gross margin: 93.6% in H1 2025.

Outlook and guidance

• Full-year XCOPRIⓇ sales guidance maintained at $420M–$450M.

• Royalties and DP/API sales guidance for the year held at KRW 65B.

• Expectation of accelerated XCOPRIⓇ growth through enhanced patient engagement and DTC campaigns.

• Continued focus on expanding global sales of XCOPRI and advancing late-stage pipeline assets.

• Strategic investments in radiopharmaceuticals and targeted protein degradation technologies.